Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M, CINV Study Group of Japan (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855–865.https://doi.org/10.1007/s10147-015-0786-7

Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, Imamura CK, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Iihara H, Ohtani S, Okuyama A, Ozawa K, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Higashi T, Hirata K (2021) Optimizing antiemetic treatment for chemotherapy induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for antiemesis. Int J Clin Oncol 26:1–17. https://doi.org/10.1007/s10147-020-01818-3

Article  PubMed  Google Scholar 

Restelli U, Saibene G, Nardulli P, Di Turi R, Bonizzoni E, Scolari F, Perrone T, Croce D, Celio L (2017) Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open 7:e015645. https://doi.org/10.1136/bmjopen-2016-015645

Article  PubMed  PubMed Central  Google Scholar 

Cawston H, Bourhis F, Eriksson J, Ruffo P, D’Agostino P, Turini M, Schwartzberg L, McGuire A (2017) NEPA, a new fixed combination of netupitant and palonosetron is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context 6:212298. https://doi.org/10.7573/dic.212298

Article  PubMed  PubMed Central  Google Scholar 

Botteman M, Nickel K, Corman S, Turini M, Binder G (2020) Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support Care Cancer 28:857–866. https://doi.org/10.1007/s00520-019-04824-y

Article  PubMed  Google Scholar 

Nilsson J, Piovesana V, Turini M, Lezzi C, Eriksson J, Aapro M (2022) Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective. Support Care Cancer 30:9307–9315. https://doi.org/10.1007/s00520-022-07339-1

Article  PubMed  PubMed Central  Google Scholar 

Tsukiyama I, Hasegawa S, Ikeda Y, Takeuchi M, Tsukiyama S, Kurose Y, Ejiri M, Sakuma M, Saito H, Arakawa I, Inoue T, Yamaguchi E, Kubo A (2018) Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy. Cancer Sci 109:2881–2888. https://doi.org/10.1111/cas.13736

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsukiyama I, Ando M, Tsukiyama S, Takeuchi M, Ejiri M, Kurose Y, Saito H, Arakawa I, Inoue T, Yamaguchi E, Kubo A (2019) Cost-utility analysis of aprepitant for patients who truly need it in Japan. Support Care Cancer 27:3749–3758. https://doi.org/10.1007/s00520-019-04672-w

Article  PubMed  Google Scholar 

Nakagawa N, Watanabe Y, Kikuchi M, Ishida T, Kisara S, Lai L (2018) A cost-effectiveness analysis of neurokinin 1 receptor antagonists for the FEC100 regimen in breast cancer. J Drug Interact Res 42:95–102

Google Scholar 

Kashiwa M, Matsushita R (2019) Comparative cost-utility analysis between aprepitant- and fosaprepitant-containing regimens to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan. Clin Ther 41:929–942. https://doi.org/10.1016/j.clinthera.2019.03.011

Article  PubMed  Google Scholar 

Hata A, Okamoto I, Inui N, Okada M, MD, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T (2022) Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol 40:180–188https://doi.org/10.1200/JCO.21.01315

Sato Y, Kondo M, Inagaki A, Komatsu H, Okada C, Naruse K, Sahashi T, Kuroda J, Ogura H, Uegaki S, Yoshida T, Mori Y, Sawada H, Watanabe S, Sugiura H, Endo Y, Yoshimoto N, Toyama T, Iida S, Yamada K, Kimura K, Wakita A (2014) Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients. J Cancer 5:390–397. https://doi.org/10.7150/jca.7706

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inano H, Morimoto Y, Kitagawa K, Shibuya A, Nakagomi K, Ota T, Anzo Y, Miyauchi R, Shono A, Watanabe K, Otori K (2024) Comparing the efficacy of fosnetupitant an NK1 receptor antagonist in CDDP-based regimens, with that of fosaprepitant and aprepitant: a retrospective observational study. Biol Pharm Bull 47:692–697. https://doi.org/10.1248/bpb.b23-00819

Article  CAS  PubMed  Google Scholar 

Humphreys S, Pellissier J, Jones A (2013) Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res 5:215–224. https://doi.org/10.2147/CMAR.S44539

Article  PubMed  PubMed Central  Google Scholar 

Matsuura K, Tsurutani J, Inoue K, Tanabe Y, Taira T, Kubota K, Tamura T, Saeki T (2022) A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer 128:1692–1698. https://doi.org/10.1002/cncr.34088

Article  CAS  PubMed  Google Scholar 

Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227. https://doi.org/10.1007/s00520-004-0710-6

Article  PubMed  Google Scholar 

Boye KS, Matza LS, Walter KN, Van Brunt KV, Palsgrove AC, Tynan A (2011) Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 12:219–230. https://doi.org/10.1007/s10198-010-0224-8

Article  PubMed  Google Scholar 

Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19:422–437. https://doi.org/10.1002/hec.1481

Article  PubMed  Google Scholar 

Ministry of Health, Labour and Welfare (2023) Medias. https://www.mhlw.go.jp/topics/medias/year/22/dl/iryouhi_data_sankou.pdf. Accessed 19 Mar 2024 (in Japanese)

Inui N, Toi Y, Yoneshima Y, Morise M, Hata A, Kubota K, Saeki T, Tamura T (2023) Pooled analysis of studies evaluating fosnetupitant and risk factors for cisplatin-induced nausea and vomiting during the extended overall phase. Adv Ther 40:4928–4944. https://doi.org/10.1007/s12325-023-02648-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shiroiwa T, Igarashi A, Fukuda T, Ikeda S (2013) WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc 11:22. https://doi.org/10.1186/1478-7547-11-22

Article  PubMed  PubMed Central  Google Scholar 

Igarashi A, Goto R, Yoneyama-Hirozane MY (2019) Willingness to pay for QALY: perspectives and contexts in Japan. J Med Econ 22:1041–1046. https://doi.org/10.1080/13696998.2019.1639186

Article  PubMed  Google Scholar